Business Context and Reporting Period
This Form 6-K filing by Mainz Biomed N.V. (noted as Quantum Cyber N.V. in metadata) covers the month of June 2025. The report details the results of the Annual General Meeting of Shareholders held on June 2, 2025. The record date for the meeting was May 5, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and shareholder voting results rather than financial performance data.
Material Changes and Voting Results
A total of 182,883 shares (5.31% of issued and outstanding shares) were present at the meeting. All 13 proposals were approved. Key voting outcomes include:
- Statutory Accounts: The annual accounts for the year ended December 31, 2024, were adopted with 150,635 votes for and 30,417 against.
- Director Discharge: Directors were discharged from liability for the 2024 financial year with 115,880 votes for and 64,373 against.
- Share Buyback Authorization: Shareholders approved the extension of the board's authorization to acquire ordinary and preferred shares.
- Share Cancellation: The cancellation of ordinary shares held by the Company was approved with 128,527 votes for and 49,017 against.
- Director Reappointments: Executive director Mr. G. Bächler and non-executive directors Mr. H.J. Hekland, Mr. G.J. Tibbitts, and Dr. H. Dreismann were reappointed.
- Auditor Appointment: Kreston Lentink Audit B.V. was assigned as the Dutch auditor, with the board authorized to assign a US auditor for the 2025 fiscal year.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The primary corporate actions involve the approval of the 2025 Omnibus Incentive Plan and amendments to the remuneration policy and articles of association.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("Quantum Cyber N.V.") and the filing registrant ("Mainz Biomed N.V.").
- Review the attached Exhibit 99.1 for detailed minutes regarding the Annual General Meeting.
- Confirm the specific terms of the 2025 Omnibus Incentive Plan and the amended remuneration policy.
- Monitor the execution of the share cancellation and the board's exercise of the new share buyback authorization.
- Check for the subsequent appointment of the US auditor as authorized by the shareholders.